Table 5.

 Case control studies of 5-aminosalicylate (5-ASA) therapy and risk of colorectal cancer in inflammatory bowel disease (IBD)

Reference	Place	Cancer cases	Adjusted OR (95% CI) for risk of cancer	Comments
Pinczowski 19947	Uppsala, Sweden	102	0.38 (0.20–0.69)	Only possible to dichotomise SASP use into < or >3 month use
Eaden 20006	England and Wales	102	0.25 (0.13–0.48)	Controls all attenders at one clinic
Bernstein 200312	Manitoba	25	1.46 (0.58–3.73)	5-ASA use within 2 y of CRC
Rutter 200413	London	68*	1.58 (0.71–3.51)†	SASP use for >10 y
			0.65 (0.26–1.62)†	Other 5-ASA use for >10 y
Terdiman 200525	US	364	0.72 (0.50–1.05)	>5 prescriptions of 5-ASA v none in the year preceding CRC
Velayos 200526	Mayo, US	188	0.60 (0.30–1.21)	>10 y 5-ASA therapy v <1 y at time of CRC diagnosis
This study 2005	England and Wales	100	0.60 (0.38–0.96)	Regular v irregular 5-ASA use in 1 y preceding CRC

*Only 14 cancer cases, remainder dysplasia or adenomas.

†Univariate analyses only.

SASP, sulfasalazine; CRC, colorectal cancer.

OR (95% CI), odds ratio (95% confidence interval).